Option Care Health, Inc. OPCH
We take great care to ensure that the data presented and summarized in this overview for Option Care Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OPCH
View all-
Black Rock Inc. New York, NY21MShares$597 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.7MShares$502 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA12.8MShares$363 Million0.07% of portfolio
-
Durable Capital Partners LP Bethesda, MD7.43MShares$211 Million1.68% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA6.21MShares$176 Million0.6% of portfolio
-
State Street Corp Boston, MA6.03MShares$171 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA4.2MShares$119 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA4MShares$114 Million0.07% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.8MShares$108 Million0.02% of portfolio
-
Morgan Stanley New York, NY3.01MShares$85.5 Million0.01% of portfolio
Latest Institutional Activity in OPCH
Top Purchases
Top Sells
About OPCH
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Insider Transactions at OPCH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 03
2025
|
Harry M Jansen Kraemer Jr Director |
BUY
Open market or private purchase
|
Direct |
38,000
+8.42%
|
$950,000
$25.98 P/Share
|
|
Oct 01
2025
|
Meenal Sethna Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,067
+50.0%
|
-
|
|
Sep 09
2025
|
Norman L. Wright Director |
BUY
Open market or private purchase
|
Direct |
3,411
+18.04%
|
$98,919
$29.31 P/Share
|
|
Aug 21
2025
|
Timothy P Sullivan Director |
BUY
Open market or private purchase
|
Direct |
20,000
+28.89%
|
$540,000
$27.51 P/Share
|
|
Aug 21
2025
|
David W Golding Director |
BUY
Open market or private purchase
|
Direct |
1,000
+0.85%
|
$27,000
$27.62 P/Share
|
|
Aug 20
2025
|
Harry M Jansen Kraemer Jr Director |
BUY
Open market or private purchase
|
Direct |
36,000
+8.75%
|
$972,000
$27.15 P/Share
|
|
Aug 20
2025
|
R Carter Pate Director |
BUY
Open market or private purchase
|
Direct |
750
+1.76%
|
$20,250
$27.19 P/Share
|
|
Aug 06
2025
|
Nicole Maggio Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,167
+21.3%
|
-
|
|
May 19
2025
|
Collin Smyser GC & Corporate Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
10,713
-11.94%
|
$353,529
$33.09 P/Share
|
|
May 19
2025
|
Collin Smyser GC & Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
11,196
+5.69%
|
-
|
|
May 14
2025
|
Barbara W. Bodem Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+29.4%
|
-
|
|
May 14
2025
|
Timothy P Sullivan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,415
+13.33%
|
$126,225
$15.9 P/Share
|
|
May 14
2025
|
R Carter Pate Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+10.9%
|
-
|
|
May 14
2025
|
Harry M Jansen Kraemer Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,056
+1.9%
|
$195,840
$15.9 P/Share
|
|
May 14
2025
|
David W Golding Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,415
+3.57%
|
$126,225
$15.9 P/Share
|
|
May 14
2025
|
Natasha Deckmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,661
+10.85%
|
$84,915
$15.9 P/Share
|
|
May 14
2025
|
Elizabeth D Bierbower Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+17.41%
|
-
|
|
May 14
2025
|
Elizabeth Quadros Betten Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+16.03%
|
-
|
|
May 14
2025
|
Eric Brandt Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+32.7%
|
-
|
|
May 14
2025
|
Norman L. Wright Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,034
+29.4%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 617K shares |
|---|---|
| Open market or private purchase | 99.2K shares |
| Exercise of conversion of derivative security | 40.7K shares |
| Payment of exercise price or tax liability | 183K shares |
|---|---|
| Open market or private sale | 31K shares |